Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation

Journal of Clinical Pathology

Volumn 66, Issue 2, 2013, Pages 140-145

  Lin, Ching Hung ^a   Liu, Jacqueline M ^b   Lu, Yen Shen ^a   Lan, Chieh ^b   Lee, Wei Chung ^a   Kuo, Kuan Ting ^a   Wang, Chung Chieh ^a   Chang, Dwan Ying ^a   Huang, Chiun Sheng ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TTY Biopharm Company Limited   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENETIC GAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SECTION; TUMOR CELL;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874656965     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200929     Document Type: Article

References (27)

1. Bentzon N, During M, Rasmussen BB, et al. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008;122:1089-94.
2. EBCTC group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98.
4. Iwase H, Omoto Y, Iwata H, et al. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer 1999;80:1982-6.
5. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21:1132-47.
6. Kondo N, Toyama T, Sugiura H, et al. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008;68:5004-8.
7. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-60.
8. Tomita S, Zhang Z, Nakano M, et al. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 2009;100:1012-17.
9. Brown LA, Hoog J, Chin SF, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:806-7; author reply 810-802.
10. Horlings HM, Bergamaschi A, Nordgard SH, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:807-8; author reply 810-802.
11. Reis-Filho JS, Drury S, Lambros MB, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:809-10; author reply 810-802.
12. Vincent-Salomon A, Raynal V, Lucchesi C, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:809; author reply 810-802.
13. Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 2011;127:345-55.
14. Lin CH, Liau JY, Lu YS, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009;18:1807-14.
15. Lin CH, Lien HC, Hu FC, et al. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B 2010;11:1-9.
16. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
17. Musholt PB, Imkamp F, von Wasielewski R, et al. RET rearrangements in archival oxyphilic thyroid tumors: new insights in tumorigenesis and classification of Hurthle cell carcinomas? Surgery 2003;134:881-9; discussion 889.
18. Chin SF, Wang Y, Thorne NP, et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007;26:1959-70.
19. Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005;65:439-47.
20. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96.
21. Holst F, Stahl PR, Ruiz C, et al. Reply: conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 2008;40:810-11.
22. Adelaide J, Finetti P, Charafe-Jauffret E, et al. Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 2008;123:2970-2.
23. Moelans CB, Monsuur HN, de Pinth JH, et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 2010;33:13-18.
24. Moelans CB, de Weger RA, Monsuur HN, et al. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 2010;23:1029-39.
25. Ooi A, Inokuchi M, Harada S, et al. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 2012;227:8-16.
26. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;27:1323-33.
27. Aguilar H, Solé X, Bonifaci N, et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010;29:6071-83.